

Pill effects on breast, ovarian CA same in high-risk women

October 22 2013



(HealthDay)—Among women who are *BRCA1/2* mutation carriers, the associations between ever use of oral contraceptives (OCs) and ovarian and breast cancers are similar to those observed in the general population, according to research published online Oct. 21 in the *Journal of Clinical Oncology*.

Patricia G. Moorman, Ph.D., of Duke University in Durham, N.C., and colleagues performed a systematic review of the literature and meta-analysis to estimate the risks of breast cancer and ovarian cancer associated with use of OCs in women at increased risk.

The researchers note that meta-analysis showed a significant inverse association between OC use and <u>ovarian cancer</u> (odds ratio [OR], 0.58; 95 percent confidence interval [CI], 0.46 to 0.73) and a non-significant



association between OC use and breast cancer (OR, 1.21; 95 percent CI, 0.93 to 1.58) for *BRCA1* and *BRCA2* mutation carriers combined. Similar patterns were observed when mutation carriers were analyzed separately.

"Our analyses suggest that associations between ever use of OCs and ovarian and breast cancer among women who are *BRCA1* or *BRCA2* mutation carriers are similar to those reported for the general population," the authors write.

More information: Abstract

Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Citation: Pill effects on breast, ovarian CA same in high-risk women (2013, October 22) retrieved 20 March 2024 from https://medicalxpress.com/news/2013-10-pill-effects-breast-ovarian-ca.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.